ZA202206835B - Method for purifying biologically active peptide by using protein a affinity chromatography - Google Patents

Method for purifying biologically active peptide by using protein a affinity chromatography

Info

Publication number
ZA202206835B
ZA202206835B ZA2022/06835A ZA202206835A ZA202206835B ZA 202206835 B ZA202206835 B ZA 202206835B ZA 2022/06835 A ZA2022/06835 A ZA 2022/06835A ZA 202206835 A ZA202206835 A ZA 202206835A ZA 202206835 B ZA202206835 B ZA 202206835B
Authority
ZA
South Africa
Prior art keywords
biologically active
active peptide
protein
affinity chromatography
containing biologically
Prior art date
Application number
ZA2022/06835A
Inventor
Song Daehae
Pak Youngdon
Jung Jinwon
Hong Junghyeon
Lim Heejin
Kim Dongin
Original Assignee
Abl Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abl Bio Inc filed Critical Abl Bio Inc
Publication of ZA202206835B publication Critical patent/ZA202206835B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166—Fluid composition conditioning, e.g. gradient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides a method for purifying an Fc-containing biologically active peptide mixture by using an affinity column comprising an affinity matrix that contains a protein A ligand, the mixture comprising a first Fc-containing biologically active peptide and a second Fc-containing biologically active peptide, wherein the second Fc-containing biologically active peptide comprises at least one more human VH3 domain than the first Fc-containing biologically active peptide. According to the purification method, biologically active peptides having the same or similar structures can be precisely separated with high purity, while process simplification is achieved.
ZA2022/06835A 2019-12-26 2022-06-20 Method for purifying biologically active peptide by using protein a affinity chromatography ZA202206835B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962953687P 2019-12-26 2019-12-26
US201962953685P 2019-12-26 2019-12-26
KR20200173808 2020-12-11
PCT/IB2020/062434 WO2021130717A1 (en) 2019-12-26 2020-12-24 Method for purifying biologically active peptide by using protein a affinity chromatography

Publications (1)

Publication Number Publication Date
ZA202206835B true ZA202206835B (en) 2023-11-29

Family

ID=76574052

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/06835A ZA202206835B (en) 2019-12-26 2022-06-20 Method for purifying biologically active peptide by using protein a affinity chromatography

Country Status (12)

Country Link
US (1) US20230212217A1 (en)
EP (1) EP4141025A4 (en)
JP (1) JP2023507923A (en)
KR (1) KR20210092280A (en)
CN (1) CN115003695A (en)
AU (1) AU2020414489A1 (en)
BR (1) BR112022011993A2 (en)
CA (1) CA3163017A1 (en)
IL (1) IL293845A (en)
MX (1) MX2022006972A (en)
WO (1) WO2021130717A1 (en)
ZA (1) ZA202206835B (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
KR20120027055A (en) 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 Readily isolated bispecific antibodies with native immunoglobulin format
EP3401337A1 (en) * 2012-09-25 2018-11-14 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
NZ720161A (en) * 2013-11-04 2022-07-29 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
AR101262A1 (en) * 2014-07-26 2016-12-07 Regeneron Pharma PURIFICATION PLATFORM FOR Bispecific Antibodies
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
CN111886251A (en) 2017-12-14 2020-11-03 Abl生物公司 Bispecific antibodies against A-SYN/IGF1R and uses thereof

Also Published As

Publication number Publication date
EP4141025A4 (en) 2024-04-24
BR112022011993A2 (en) 2022-09-20
US20230212217A1 (en) 2023-07-06
WO2021130717A1 (en) 2021-07-01
KR20210092280A (en) 2021-07-23
JP2023507923A (en) 2023-02-28
MX2022006972A (en) 2022-08-04
EP4141025A1 (en) 2023-03-01
IL293845A (en) 2022-08-01
CN115003695A (en) 2022-09-02
CA3163017A1 (en) 2021-07-01
AU2020414489A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
NO20072863L (en) Procedure for Purifying FSH
BR112018003127A2 (en) fkpa purification and uses thereof to produce recombinant polypeptides
SG10201908027QA (en) Use of alkaline washes during chromatography to remove impurities
NZ587511A (en) Purified lymphotoxin-beta-receptor immunoglobulin fusion proteins and methods of their purification
MX2020003798A (en) Methods for purification of arylsulfatase a.
PH12020500027A1 (en) Purification of iduronate-2-sulfatase
PE20121033A1 (en) RECOMBINANT PRODUCTION OF PEPTIDES
NO20072661L (en) Purification of glycopeptides
MX2019007995A (en) Novel polypeptide and method for producing imp using same.
WO2015021423A3 (en) Purification of chimeric fviii molecules
NZ781138A (en) Anti-vegf protein compositions and methods for producing the same
IN2014CH00378A (en)
MX2016013416A (en) Novel purification process of gonadotropin.
WO2020186155A3 (en) Synthetic neuromodulatory peptides
ZA202206835B (en) Method for purifying biologically active peptide by using protein a affinity chromatography
ES2090840T3 (en) PURIFICATION PROCEDURE OF A HYDROFLUOROALCAN.
MX2022007679A (en) Purified compositions of enteroviruses and methods of purification with glutathione affinity chromatography.
UA85741C2 (en) Method the production of the immunoglobulin
WO2020164721A8 (en) Chromatographic purification of at least one enzyme selected from the group consisting of collagenase type i, collagenase type ii, neutral protease, and clostripain
MX2022002628A (en) Fusion proteins and uses thereof.
BR112021024417A2 (en) Methods for removing unwanted components during multi-stage chromatographic processes
PT1558354E (en) Using amines, amino acids or amino acid esters as mobile phase modifiers in chromatography
ATE395360T1 (en) NEW METHOD FOR PURIFYING HUMAN GROWTH HORMONE
MX2021016092A (en) Methods for protein purification.
WO2023205752A3 (en) Ephrin ligand mimetic peptides for the treatment of neurodegenerative diseases